OP-1
Commercial- Indications
- Bone regeneration, Spinal fusion
Company intelligence / Profile preview
Olympus Biotech
Hopkinton, Massachusetts, United Statesolympus-global.com ↗
- Ownership
- Private
- Employees
- ~23
- Development stage
- Commercial
01
Overview
Olympus Biotech focused on regenerative medicines to improve patient quality of life. Its key asset was Osteogenic Protein‑1 (OP‑1), acquired from Stryker Biotech in 2011. The company aimed to develop and distribute therapies stimulating tissue regeneration but discontinued its US biotechnology operations in 2014[6].
- Therapeutic areas
- Rheumatology
- Modalities
- Regenerative medicineCell therapyGene therapyTissue engineering
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Olympus Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Olympus Biotech.